Effects of ozanimod

ozanimod was shown to be effective in reducing the number of relapses in two major studies involving 2,666 patients with relapsing-remitting multiple sclerosis (RRMS). In the first one-year study, patients treated with standard-dose ozanimod had about half as many relapses per year on average as those treated with another drug, interferon beta-1a (0.18 versus 0.35 relapses). In the second study, which lasted two years, patients treated with standard-dose ozanimod relapsed an average of 0.17 times per year.

A major study shows that ozanimod, used with aminosalicylates (anti-inflammatory drugs) and/or corticosteroids, is more effective than placebo (dummy treatment) in producing or maintaining remission (a period in which the disease is inactive or causes significant symptoms) in adults with moderate to severe ulcerative colitis in whom standard treatments or biologic treatments are not effective enough or cannot be used. As a result of 42 weeks of maintenance treatment, after induction treatment, approximately 18% of patients taking Ozamod achieved remission; after maintenance treatment, approximately 37% of patients taking Ozamod achieved remission.

The original drug Ozamod has been launched in China, but it has been on the market for a short time and has not been included in the medical insurance. The specific price is not yet clear, and domestic purchase channels are relatively difficult. The price of Ozamod original drug specifications0.92*28 capsules per box listed overseas may be around 19,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There is currently no generic version of Ozamod produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.